A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

Trial Profile

A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Hydroxychloroquine (Primary) ; Vemurafenib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Jan 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jan 2016, as reported by ClinicalTrials.gov.
    • 22 Jan 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 14 Dec 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jun 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top